India, Oct. 25 -- Johnson & Johnson (JNJ) reported encouraging Phase 1 clinical data for JNJ-6143, an investigational oral therapy for advanced prostate cancer, highlighting significant anti-tumor activity in patients who had previously undergone multiple lines of treatment.
JNJ-6143, formerly known as HLD-0915, is a once-daily oral Regulated Induced Proximity Targeting Chimera (RIPTAC) small molecule designed to selectively target cancer cells. The study evaluated the drug in patients with advanced prostate cancer who had exhausted several prior treatment options, an area where unmet medical need remains high.
Among 16 patients with measurable disease, 75% achieved a confirmed complete or partial response based on Response Evaluation Cri...